News and Trends 5 Oct 2022 Araris Biotech closes $24M financing round for ADCs Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million… October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2021 ADC Approval Buoys Spirits in Cancer Treatment Space The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the… May 11, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies …technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These promising… December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 Legochem Bioscience signs agreement with Glycotope to develop cancer drug …GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of biopharmaceutical drugs designed as a… July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 23 Oct 2019 Channeling the Power of AI into Personalizing Medicine …established biotech Cambridge Antibody Technology. “I wanted to make a difference to patients’ lives — this was something that really interested me about human biology. That’s why I did biochemistry… October 23, 2019 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Nov 2024 8 biotech companies advancing new treatments for breast cancer in 2024 …to create individualized treatment options. BNT323 is an antibody-drug conjugate (ADC) targeting HER2-expressing cancers, including HER2-low metastatic breast cancer. ADCs combine the specificity of monoclonal antibodies with the potency of… November 14, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 4 Feb 2025 World Cancer Day: trends in cancer therapeutics to look forward to in 2025 …– is bound to a drug or monoclonal antibody, it attaches itself to cancer cells, much like a key to a lock. Then, with the help of nuclear imaging, the… February 4, 2025 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2017 German Biotech Reels in €34M for its Cancer-Killing Technology Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development… November 21, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2025 AstraZeneca bets on Asia: a surge of deals in March amid fraud probe …BioMed to gain an option to license multiple programs derived from the latter’s Harbour Mice fully human antibody technology platform. The platform creates heavy chain antibodies – around half the… March 31, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Dec 2017 Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017 …previous studies. The drug is a bispecific antibody that binds both factor IXa and factor X, both of which are vital for coagulation. Its accelerated approval from the FDA based… December 18, 2017 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 24 Apr 2024 Overcoming toxicities: are IL-2 smart cytokines the next big thing? …the race to get its IL-2 superkine to the market is Swiss-Italian biotech Philogen. Its clinical feat Darleukin is made up of the L19 antibody, which is fused to a… April 24, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA boosts Antengene pancreatic cancer treatment Biopharma company Antengene Corporation Limited says ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration… September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email